News | August 07, 2008

TomoTherapy to Introduce TomoDirect at ESTRO, ASTRO Annual Meetings

August 8, 2008 - TomoTherapy Inc. will introduce the TomoDirect discrete-angle delivery mode for the TomoTherapy Hi-Art treatment system at European Society for Therapeutic radiology and Oncology (ESTRO) in Gothenburg, Sweden, Sept. 14-18, 2008, and the American Society for Therapeutic radiology and Oncology (ASTRO) in Boston, MA, Sept. 21-25, 2008.

This new technology allows Hi-Art system users to quickly plan and deliver advanced TomoTherapySM radiation treatments with a series of linear beam paths, rather than the existing helical path, said the manufacturer. With TomoDirect, clinicians can choose several discrete angles and the optimal modulation level required for delivery, based on specific patient therapy goals.

TomoDirect was developed as a complement to helical TomoTherapy, with both utilizing the same binary multi-leaf collimator and CT-style gantry technology. The choice of which modality to use for a given case will depend on the nature of the tumor volume and surrounding organs at risk. TomoDirect is expected to provide time savings in both the planning and delivery phases for several clinical scenarios, including whole breast irradiation and palliative treatments.

TomoDirect research partner Paul Read, M.D., Ph.D., assistant professor of Radiation Oncology, University of Virginia, said, "TomoDirect will expand the spectrum of external beam radiation therapy patients who can be optimally treated with TomoTherapy's unique image-guided, intensity-modulated radiation therapy (IG-IMRT). Now, we will have an option to deliver dose via two unique and complementary delivery modes, choosing whichever provides the optimal dose distribution. Clearly, breast cancer patients will benefit from TomoDirect, and other disease sites will likely be developed for which there is clinical benefit."

Added research partner Prof. Guy Storme, M.D., Ph.D., director of the Oncologic Center at UZ Brussel, Brussels, Belgium: "Certainly, with the combination of helical and direct deliveries, TomoTherapy should offer significant benefit for a majority of breast cancer treatments. It will provide the ability to choose and apply the right modality for the best treatment. Our research is focused on providing comprehensive usage guidelines as we study and validate this new mode combination."

In addition to the added capabilities offered by TomoDirect, the Hi-Art system's treatment modes are being expanded to include a 3D conformal option, thereby meeting the full range of options needed for all clinical cases.

TomoTherapy is planning to make TomoDirect available to radiation clinics in summer 2009. As a product pending FDA 510(k) clearance, TomoDirect is not yet available for sale in the U.S.

For more information: www.tomotherapy.com

Related Content

Philips Unveils IntelliSpace Radiation Oncology at ESTRO 2019
News | Oncology Information Management Systems (OIMS) | April 25, 2019
Philips announced IntelliSpace Radiation Oncology, an intelligent patient management solution to manage complexity,...
ZON-PTC in Clinical Use With RayStation 8B and Hyperscan
News | Treatment Planning | March 19, 2019
Zuid-Oost Nederland Protonen Therapie Centrum (ZON-PTC), Maastricht, Netherlands, recently treated its first patient...
Mississippi Cancer Center Combines RayStation and TomoTherapy for Prostate Cancer Case
News | Treatment Planning | March 08, 2019
Anderson Regional Cancer Center in Meridian, Miss., has treated its first patient using the combination of RaySearch's...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...